Molino M, Woolkalis M J, Reavey-Cantwell J, Praticó D, Andrade-Gordon P, Barnathan E S, Brass L F
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
J Biol Chem. 1997 Apr 25;272(17):11133-41. doi: 10.1074/jbc.272.17.11133.
Human endothelial cells express thrombin receptors and PAR-2, the two known members of the family of protease-activated G protein-coupled receptors. Because previous studies have shown that the biology of the human thrombin receptor varies according to the cell in which it is expressed, we have taken advantage of the presence of both receptors in endothelial cells to examine the enabling and disabling interactions with candidate proteases likely to be encountered in and around the vascular space to compare the responses elicited by the two receptors when they are present in the same cell and to compare the mechanisms of thrombin receptor and PAR-2 clearance and replacement in a common cellular environment. Of the proteases that were tested, only trypsin activated both receptors. Cathepsin G, which disables thrombin receptors, had no effect on PAR-2, while urokinase, kallikrein, and coagulation factors IXa, Xa, XIa, and XIIa neither substantially activated nor noticeably disabled either receptor. Like thrombin receptors, activation of PAR-2 caused pertussis toxin-sensitive phospholipase C activation as well as activation of phospholipase A2, leading to the release of PGI2. Concurrent activation of both receptors caused a greater response than activation of either alone. It also abolished a subsequent response to the PAR-2 agonist peptide, SLIGRL, while only partially inhibiting the response to the agonist peptide, SFLLRN, which activates both receptors. After proteolytic or nonproteolytic activation, PAR-2, like thrombin receptors, was cleared from the endothelial cell surface and then rapidly replaced with new receptors by a process that does not require protein synthesis. Selective activation of either receptor had no effect on the clearance of the other. These results suggest that the expression of both thrombin receptors and PAR-2 on endothelial cells serves more to extend the range of proteases to which the cells can respond than it does to extend the range of potential responses. The results also show that proteases that can disable these receptors can distinguish between them, just as do most of the proteases that activate them. Finally, the residual response to SFLLRN after activation of thrombin receptors and PAR-2 raises the possibility that a third, as yet unidentified member of this family is expressed on endothelial cells, one that is activated by neither thrombin nor trypsin.
人内皮细胞表达凝血酶受体和PAR-2,这是蛋白酶激活的G蛋白偶联受体家族中两个已知的成员。由于先前的研究表明,人凝血酶受体的生物学特性因其表达的细胞不同而有所差异,我们利用内皮细胞中同时存在这两种受体的情况,来研究与血管腔内及周围可能遇到的候选蛋白酶之间的促进和抑制相互作用,比较当两种受体存在于同一细胞中时它们引发的反应,并比较在共同细胞环境中凝血酶受体和PAR-2的清除及替代机制。在所测试的蛋白酶中,只有胰蛋白酶能激活这两种受体。能使凝血酶受体失活的组织蛋白酶G对PAR-2没有影响,而尿激酶、激肽释放酶以及凝血因子IXa、Xa、XIa和XIIa既不能显著激活也不能明显使任何一种受体失活。与凝血酶受体一样,PAR-2的激活会导致百日咳毒素敏感的磷脂酶C激活以及磷脂酶A2的激活,从而导致前列环素(PGI2)的释放。两种受体同时激活所引发的反应比单独激活其中任何一种受体时都要强烈。它还消除了随后对PAR-2激动剂肽SLIGRL的反应,而仅部分抑制了对能激活两种受体的激动剂肽SFLLRN的反应。在经过蛋白水解或非蛋白水解激活后,PAR-2与凝血酶受体一样,从内皮细胞表面清除,然后通过一个不需要蛋白质合成的过程迅速被新的受体替代。选择性激活其中任何一种受体对另一种受体的清除没有影响。这些结果表明,内皮细胞上凝血酶受体和PAR-2的表达更多地是为了扩大细胞能够响应的蛋白酶范围,而不是为了扩大潜在反应的范围。结果还表明,能够使这些受体失活的蛋白酶可以区分它们,就像大多数激活它们的蛋白酶一样。最后,凝血酶受体和PAR-2激活后对SFLLRN的残余反应增加了这样一种可能性,即该家族中第三个尚未鉴定的成员在内皮细胞上表达,它既不被凝血酶也不被胰蛋白酶激活。